InvestorsHub Logo
Followers 91
Posts 28831
Boards Moderated 2
Alias Born 04/19/2013

Re: Bluesummers post# 258498

Friday, 05/26/2017 6:48:49 PM

Friday, May 26, 2017 6:48:49 PM

Post# of 400674
Maybe the bar is so low, its not in perspective

Again, how many pharma. companies can you say that about on the OTC?



I have yet to find one of similar category of niche' attributes on the OTC.



See, if one compares any company using the companies on the OTC as the gold standard, well, almost any company is going to come out smelling like roses.

Thats because comparing anything to OTC companies is like comparing it to feces, vomit or snot. Low standards beget low standards and inferiority. Then the outcome is meaningless

The fact Elite fancies itself a drug developer and manufacturer is not an attribute! At least not in the real world, sans penny stocks. High risk/high reward drug developers fetch higher premiums and market valuations because they are single purposed and wholly dedicated to developing blockbuster new drugs.

A tiny drug developer with a tiny pipeline, splitting capital and resources with different objectives (drug developing/manufacturing) ceases to be and obtain new drug developer valuations.

This is where Elite is, with very little in its pipeline as a signature new drug. Its valuation should be heavily weighed as a manufacturer...which is one of many reasons it is wildly over valued.. The main reason is its a sleaze ball penny stock supported by generally unsophisticated investors

Notice the lack of institutional ownership, lack of traditional funding sources, lack of an investment banker, lack of a strategic investor, lack of corp governance and so on
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News